Lihavuus

Semaglutide was associated with a lower rate of bone fractures and greater reductions in body mass index among adults with type 2 diabetes, according to a retrospective analysis presented at the Endocrine Society’s ENDO 2026 meeting in Chicago.

14. kesäkuuta 2026 Raportoinut AI

Starting this Monday, social security covers Mounjaro and Wegovy for patients with severe obesity or diabetes. It is a first in Europe.

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

05. toukokuuta 2026 Raportoinut AI Faktatarkistettu

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Researchers at Vanderbilt Health discovered that both popular weight loss drugs and bariatric surgery significantly reduce fat mass while causing modest losses in fat-free mass, including muscle, in patients with obesity. The findings, based on over 3,000 patients, show improvements in overall body composition over 24 months. Maintaining this balance is crucial for long-term health, the study emphasizes.

06. huhtikuuta 2026 Raportoinut AI Faktatarkistettu

Astrocytes—cells once widely described primarily as neuronal support—may be key intermediaries in how the brain translates a post-meal rise in glucose into satiety signals, according to a study published April 6, 2026, in the Proceedings of the National Academy of Sciences.